Sign In
Buy RCKT
$2.92
+0.0300 (+1.04%)
At Close: Jun 03, 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
12:36pm, Wednesday, 27'th Mar 2024
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals' Promising Path In Gene Therapy
06:03pm, Friday, 01'st Mar 2024
Rocket Pharmaceuticals, Inc. stock surged 76% post a "Buy" recommendation, fueled by positive Phase 2 trial news for RP-A501 in Danon disease. RP-A501, targeting a rare disease without current treatme
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
01:21pm, Tuesday, 27'th Feb 2024
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
04:01pm, Monday, 26'th Feb 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
7 Speculative Stocks to Double Your Money THIS Year
10:14pm, Monday, 22'nd Jan 2024
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 02'nd Jan 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
07:00am, Tuesday, 12'th Dec 2023
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
12:47pm, Wednesday, 15'th Nov 2023
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
11:17am, Thursday, 09'th Nov 2023
The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
04:04pm, Monday, 06'th Nov 2023
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
09:45am, Saturday, 23'rd Sep 2023
Rocket Pharmaceuticals has two programs approaching commercialization. By contrast, Intellia's candidates won't be ready for quite some time.
Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week
12:01pm, Friday, 15'th Sep 2023
Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.
